Dr. rer. nat. Ludger Grosse-Hovest

Dr. Ludger Grosse-Hovest graduated in biology in the area of immunology. For more than 25 years, he has been working in the field of recombinant therapeutical antibodies for cancer treatment and has been developing new antibody forms. Until 2012, he acted as the lead of a work group at the Institute of Immunology at Eberhard-Karls University in Tübingen. After receiving an award from the German Federal Ministry of Education and Research (BMBF), he cofounded the biotech company Synimmune GmbH in 2012. Until today, he is the CEO and scientific lead of Synimmune GmbH.